**Wake Forest NCORP Research Base**

**Bi-Weekly Broadcast**

**March 12, 2020**

**WAKE NCORP Website link** <https://wakencorp.phs.wakehealth.edu/>



**Mark Your Calendars** Wake Forest NCORP Research Base Annual Meeting, October 29 – October 31, 2020 at the Grand Dunes Resort in Myrtle Beach, SC.

**NEW TRAVEL AWARDS FOR PRIORITY ACCRUALS in 2020:**

The Wake Forest NCORP Research Base will offer travel awards to cover two nights hotel accommodations at the Wake Forest NCORP 2020 Annual Meeting for NCORP Community and M/U Community sites that accrue the highest number of racial/ethnic minority (WF 10217 & WF 1802) and rural patients (WF 30917CD), see below. Two travel awards per study will be offered for each of the following protocols:

* TELEHEALTH: WF 30917CD (all accruals between 1/1/2020 and 8/31/2020)
* PCW: WF 1802 (all accruals to AA and/or low-income strata between 1/1/2020 and 8/31/2020)
* WAYS: WF 10217 (all accruals between 1/1/2020 and 04/30/2020; This study is closing to enrollment 5/1/2020)

**STUDY UPDATES:**


* **WF-1803CD-CAREGIVERS**

**\*\*\*Complete the rostering survey for enrollment by March 18, 2020\*\*\***

* + If you would like to participate in this study, please start the rostering process before this date. If you have any questions regarding this process, please contact [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu)

[WF1803CD - Practice Group Rostering and Component/Subcomponent Eligibility & Registration](https://redcap.wakehealth.edu/redcapccc/surveys/?s=WPMTHP8A3N)

* + Data collection for this study will end on or around April 30, 2020.
* **WF 1802 PCW – *Influence of Primary Treatment for Prostate Cancer on Work Experience***
  + The **Moderate to High Income, White** stratum is **CLOSED**.
  + You can determine the remaining slots left for any stratum by going to **CTSU-OPEN** -> **Slot Reservation** -> **Report**. Please see screenshot below.



* + This study compares changes in work ability reported by African American and white prostate cancer survivors with higher and lower incomes. If you would like for the **Wake Forest Health Equity Core team** to contact you regarding ideas to help increase recruitment of African American and low income participants, please email [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).
  + **Next Site Call** will be held March 17 at 1:30pm. If you have not received the WebEx invitation and desire to join us, or if your site is interested in becoming part of this study and would like more information, please email [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).

**NEW AMENDMENT FOR WF1801**

* **WF-1801 Ramipril – *A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy* Amendment 4, Protocol Version Date 09/24/2019, Release Date 03/16/2020:**
* The amended protocol and related documents will be released on **March 16, 2020** and will be made available on the [CTSU](https://www.ctsu.org/Public/Default.aspx?ReturnUrl=%2f) website. The enrollment form in OPEN will be updated and posted on the [WAKENCORP](https://wakencorp.phs.wakehealth.edu/dspLogin.cfm) site.
* A brief summary of the updates with this amendment is listed below. Other changes are listed in the Summary of Changes document that will be posted to CTSU.
* The inclusion and exclusion criteria was updated to clarify eligibility, we included language from ASCO related to prior malignancies.
* The baseline potassium eligibility language was updated.
* The Comprehensive Metabolic Panel (CMP) instructions were modified to allow sites to use local standard of care labs for Ramipril titration only in specific situations.
* The GFR toxicity criteria was removed and specific instructions on how to use the serum creatinine value to guide Ramipril titration was added.
* **Note - Limited Access Case Report Forms:** Online access to CRF 17-20 (Baseline Assessment, 6 Week Assessment, 10 Week Assessment, 22 Week Assessment) is restricted to neurocognitive test certified site personnel only and can be downloaded from the Protocol Documents page of the Wake Forest NCORP Research Base (WF NCORP RB) member website, [WAKENCORP](https://wakencorp.phs.wakehealth.edu/dspLogin.cfm). For site staff who have questions or need to complete the neurocognitive test certification, please contact the WF NCORP RB at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).
* **WF 1805CD HN Star – *Implementation and Effectiveness Trial of HN Star***
  + In order to provide the most effective launch of this study, we are making a few adjustments to the software tool that will be used for this study, therefore the activation date for this study will be closer to the end of March or the first of April. Please bear with us as many of you have voiced an interest in this study and we are eager to push this out to you.
* **WF 30917CD Telehealth – *A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors***
  + **Amendment #4 has been submitted for approval**, the following changes are coming soon:
    - **Opening Telehealth to all sites**. All sites will be able to view the protocol on CTSU and participate, as long as there is a study-trained provider (therapist) in the state in which the rural residing participant resides. A reminder, this study will enroll rural residing residents only. Both the lists of states with a trained provider (therapists) and eligible rural zip codes can be found on the [WAKENCORP](https://wakencorp.phs.wakehealth.edu/dspLogin.cfm) website.
    - **Shortening the screening process** by removing the TICS-m
  + **The next Site Call** is Monday, March 16th from 4-5 EST. Interested sites are encouraged to attend. If you have questions beforehand, please email [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).
* **WF 1806 M&M – *Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer.***
  + Please remember to submit your source documents (1st and 3rd patient;Cycles 1 – 4) for review as real-time as possible. Source documents will be used to ensure that consistent toxicity reporting is being done across the NCORP sites and it is best to address any disparities early.
* **WF 98213 PREVENT – *Preventing Anthracycline Cardiovascular Toxicity with Statins***
  + Reminder for those that may have patients coming back in for their 24 month follow-up, please make sure to schedule, remind your patients of this important visit, collect the data and send data into [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) .
* **EAQ161CD - BIOMARKERS**

The deadline to complete rostering for the EAQ161CD Biomarkers study is **March 31, 2020**. If you would like to participate in this important CCDR study, please follow this link to get started:

[EAQ161CD - Site Rostering Survey](https://redcap.wakehealth.edu/redcapccc/surveys/?s=FPDWTEJCH3)

Please contact [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) if you have any questions.

**General Site email address**: If your site has a general email address that you would like for WF NCORP RB to use in order to assure that your site gets all of the Bi-Weekly and Special Broadcasts, please send that email along with your site name and CTEP ID to [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu).

**General Biospecimen Lab Management:**

* Please request your lab kits before you run completely out of kits. This will ensure that there will be no delay in getting samples shipped to the Biospecimen Laboratory.
* Please do not ship samples on Thursday or Friday so that samples will not arrive on the weekend.
* **Accruals as of March 11, 2020**

|  |  |  |  |
| --- | --- | --- | --- |
| **Open Studies** | **Name** | **Enrolled** | **Target** |
| WF 97115 | Acupuncture | 212 | 240 |
| WF 97116 | Remember | 251 | 276 |
| WF 97415 | Upbeat | 251 | 1000 |
| WF 10217 | Ways | 206 | 220 |
| WF 20817CD | OaSiS | 1,097 | 1114 |
| WF 30917CD | Telehealth | 30 | 90 |
| WF 1801 | Ramipril | 29 | 75 |
| WF 1802 | PCW | 75 | 220 |
| WF 1803CD | Caregivers | 727 | 828 |
| WF 1804CD | AH-HA | 0 | 624 |
| WF 1806 | M&M | 15 | 300 |
| EAQ161CD | Biomarker Survey | 55 | 201 |